Vigil Neuroscience (VIGL) Guggenheim SMID Cap Biotech Conference summary

Company strategy and scientific focus

• Focused on developing therapeutics targeting microglia to address neuroinflammation in neurodegenerative diseases, with TREM2 as the key genetically validated target.

• Utilizes a precision-based approach, selecting indications with strong genetic and mechanistic links to microglia dysfunction.

• Differentiates itself by having two TREM2 agonists in clinical development: a monoclonal antibody (VGL101) and a first-in-class small molecule.

• Small molecule program recently completed a robust Phase 1 study, showing strong safety, tolerability, and biomarker engagement.

• Strategic partnership with Sanofi includes a $40 million investment and right of first negotiation on the small molecule program.

Clinical development and milestones

• VGL101 (antibody) is in a Phase 2 open-label study (IGNITE) for ALSP, with top-line data expected in Q2; study includes monthly IV dosing over 12 months in 20 patients.

• Small molecule TREM2 agonist is Phase 2 ready for Alzheimer's disease (AD), with initiation planned for Q3.

• Full Phase 1 data for the small molecule will be presented at the AD/PD conference in April, highlighting safety, PK/PD, and biomarker response.

• Phase 2 design for the small molecule in AD will be finalized in alignment with a partner and regulatory input.

• Natural history study (ILLUMINATE) in ALSP has over 50 patients and informs biomarker selection and disease progression.

Key scientific findings and biomarker strategy

• TREM2 agonism shown to convert microglia to a neuroprotective state, addressing multiple neuropathologies beyond amyloid.

• Small molecule demonstrates potent, synergistic effects and superior target engagement compared to antibody, with robust reduction in soluble TREM2 (up to 50%).

• Soluble TREM2 is a highly specific and functional biomarker for microglia activation and target engagement.

• Phase 1 data support once-daily 25 mg dosing for the small molecule, with consistent biomarker response across healthy, elderly, and AD cohorts.

• Phase 2 in AD will include additional biomarkers such as GFAP and amyloid reduction.